| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Erratum to: Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
|
Maggo, Simran D. S.
|
|
2016
|
55 |
4 |
p. 437
|
article
|
| 2 |
Impact of New Genomic Technologies on Understanding Adverse Drug Reactions
|
Maggo, Simran D. S.
|
|
2015
|
55 |
4 |
p. 419-436
|
article
|
| 3 |
Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015 % and Timolol 0.5 % in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies
|
Kaarniranta, Kai
|
|
2015
|
55 |
4 |
p. 485-494
|
article
|
| 4 |
Population Pharmacokinetic Analysis of Lanreotide Autogel®/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials
|
Buil-Bruna, Núria
|
|
2015
|
55 |
4 |
p. 461-473
|
article
|
| 5 |
Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA
|
Wagner, Christian
|
|
2015
|
55 |
4 |
p. 475-483
|
article
|
| 6 |
The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers
|
Morrissey, Kari M.
|
|
2015
|
55 |
4 |
p. 495-506
|
article
|
| 7 |
The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
|
Echizen, Hirotoshi
|
|
2015
|
55 |
4 |
p. 409-418
|
article
|
| 8 |
Therapeutic Concentrations of Metformin: A Systematic Review
|
Kajbaf, Farshad
|
|
2015
|
55 |
4 |
p. 439-459
|
article
|
Journal description